The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases

What You Need to Know About COVID-19 & Therapies for Rheumatic Diseases

December 6, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PHILADELPHIA—Since March 2020, the world has been turned upside down by the COVID-19 pandemic. Rheumatologists must understand how to best protect and treat their patients with autoimmune conditions at risk for infection due to immunosuppressive therapy. At ACR Convergence 2022, the session titled, Latest COVID and Rheumatic Disease Therapies: What You Need to Know, provided a helpful review of this essential clinical topic.

You Might Also Like
  • Outcomes in Patients with Rheumatic Diseases & COVID-19
  • Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19
  • German Society Updates Rheumatic Diseases Guidelines in Light of COVID-19 Pandemic
Also By This Author
  • The Many Facets of JIA: Insights from Bench to Bedside for the Clinical Care of Patients with JIA

Guidance

The first speaker was Rachael Perritt, PharmD, BCPS, clinical pharmacy specialist (ambulatory) at Penn Medicine, University of Pennsylvania Health System, Philadelphia. Dr. Perritt began her presentation by noting that patients with rheumatic diseases are at increased risk of developing—and dying from—COVID-19, compared with the general population. Specific risk factors for infection and death include being male; being age 65 or older; and having moderate to high rheumatic disease activity, hypertension or other cardiovascular diseases, and chronic lung diseases. She also noted that certain immunosuppressive medications, such as rituximab, sulfasalazine and glucocorticoids prescribed at more than 10 mg per day, have been shown to increase the risk of death from COVID-19.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Many clinicians are surprised to see sulfasalazine on this list, Dr. Perritt pointed out. She said this finding may be due to the characteristics of patients who are recommended for treatment with sulfasalazine (i.e., patients perceived to have higher baseline risk of infection may be preferentially treated with sulfasalazine over other disease-modifying anti-rheumatic drugs [DMARDs], and thus, these patients are more likely to experience severe COVID-19 disease).

Dr. Perritt helped summarize general guidance from the ACR with respect to treating patients in the era of COVID-19, such as recommending social distancing, reducing in-person healthcare encounters when possible and using the lowest possible dose of glucocorticoids.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

With respect to new medications and escalation of therapy, the ACR guidance is to start hydroxychloroquine or chloroquine at full dose for patients with systemic lupus erythematosus and inflammatory arthritis conditions and starting biologics for inflammatory arthritis if there is moderate to high disease activity that is uncontrolled by conventional synthetic DMARDs (csDMARDs).

Vaccination against COVID-19 is clearly recommended for all patients and their family members, and patients should seek vaccination when disease is quiescent.

Dr. Perritt made reference to the ACR COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases, which provides detailed recommendations relating to many different immunosuppressive treatments and how these should be handled relative to timing of vaccination.1 In particular, Dr. Perritt explained that, for patients to be treated with rituximab, it is ideal to perform vaccination against COVID-19 at least 2–4 weeks before rituximab dosing.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Meeting Reports Tagged With: ACR Convergence 2022, COVID-19

You Might Also Like:
  • Outcomes in Patients with Rheumatic Diseases & COVID-19
  • Some Rheumatic Diseases Tied to Higher Risk of Severe COVID-19
  • German Society Updates Rheumatic Diseases Guidelines in Light of COVID-19 Pandemic
  • People with Rheumatic Diseases Should Pay Extra Attention to Self-Care During COVID-19

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)